<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is the most common <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (ARL) in childhood </plain></SENT>
<SENT sid="1" pm="."><plain>The major issues in adult and pediatric ARL include identifying the optimal chemotherapy regimen and the concurrent treatment of both rituximab and highly active anti-retroviral therapy (HAART) </plain></SENT>
<SENT sid="2" pm="."><plain>We present a case of advanced stage Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in an 8-year-old female with acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>), who was successfully treated with a 3 month course of modified CHOP-R (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="41977">daunorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="8382">prednisone</z:chebi>, and rituximab) and HAART therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The combination of rituximab and chemotherapy with HAART therapy may be well-tolerated and effective in HIV/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> patients with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>